QTZM · Quantumzyme Corp.

This confirmatory Intellectual Property Assignment Agreement resolves potential ambiguity regarding ownership of a core patent application central to Quantum Genesis AI Corp.’s enzyme catalyst platform. By formally assigning US20250146029A1 — which covers modified polypeptides enabling enzymatic ibuprofen synthesis — the Company secures unencumbered, retroactive title effective November 2, 2023, aligning with the original filing date and the parties’ intent under the February 2023 Asset Purchase Agreement. The agreement explicitly extinguishes any retained rights by CEO Naveen Kulkarni and includes comprehensive representations on ownership clarity, freedom from encumbrances, and non-infringement, reducing future litigation or title risk. Strategically, this strengthens the Company’s proprietary position in biocatalytic pharmaceutical synthesis — a domain with high technical barriers and commercial relevance to green chemistry and API manufacturing. Because the patent application stems from technology transferred under the APA, the assignment does not represent new consideration or operational change, but rather legal reinforcement of existing asset control. For investors, this enhances confidence in the durability and defensibility of the Company’s core IP portfolio, particularly as it may underpin future partnerships, licensing, or product development milestones tied to enzymatic small-molecule synthesis.